Upcoming Financial Results, Recent Investments and Agreements, and Expanded Collaborations - Analyst Notes on PerkinElmer, PAREXEL, WuXi, Response Genetics, and Foundation Medicine
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding PerkinElmer, Inc. (NYSE: PKI), PAREXEL International Corporation (NASDAQ: PRXL), WuXi PharmaTech (Cayman) Inc. (NYSE: WX), Response Genetics, Inc. (NASDAQ: RGDX), and Foundation Medicine, Inc. (NASDAQ: FMI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Technical Analysis on Top Gainers -- Research on Response Genetics, Gol Linhas Aereas Inteligentes, Gastar Exploration, and China Finance Online
PR Newswire - Fri Apr 04, 11:47AM CDT
The US markets saw a negative sentiment on Thursday, April 03, 2014, with the NASDAQ Composite closing at 4,237.74, down 0.91%, the Dow Jones Industrial Average ending the session flat at 16,572.55, and the S&P 500 edging 0.11% lower to finish the trading session at 1,888.77. The session saw a positive impact from Telecommunication Services, Energy and Utilities sectors along with a drag from Information Technology, Consumer Discretionary and Health Care sectors. A number of stocks saw large movements, including Response Genetics Inc. (NASDAQ: RGDX), Gol Linhas Aereas Inteligentes S.A. (NYSE: GOL), Gastar Exploration Inc. (NYSE MKT: GST) and China Finance Online Co. Ltd (NASDAQ: JRJC). Free technical research on RGDX, GOL, GST and JRJC can be downloaded upon signing up at:
Response Genetics (RGDX) in Focus: Stock Up 18.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 8:39AM CDT
Response Genetics, Inc was a big mover last session, as its shares rose over 18% on the day.
Kellogg Company Rises on Possible Takeover Suspicions; Amazon Releases Fire TV
ACCESSWIRE - Thu Apr 03, 11:21PM CDT
Kellogg Company (NYSE: K) - For an in-depth report on Kellogg Company follow: www.BullTrends.com/stockquote/K
Why Response Genetics (RGDX) Stock Is Soaring Today
at The Street - Thu Apr 03, 9:25AM CDT
Response Genetics (RGDX) surged on Thursday after the molecular diagnostic test developer announced contracts with six new provider networks, which increases its total membership to more than 174 million U.S. members. The contracts span 10 states and...
Response Genetics, Inc. Announces Contracts With Six New Provider Networks
GlobeNewswire - Thu Apr 03, 6:00AM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that it has signed agreements with six additional health plans across 10 states bringing the Company's total national contracted membership to more than 174 million lives.
Response Genetics, Inc. Announces Fourth Quarter and Year-End 2013 Financial Results
GlobeNewswire - Thu Mar 20, 6:01AM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced its consolidated financial results and business progress for the fourth quarter and full year ended December 31, 2013.
Response Genetics, Inc. to Release Fourth Quarter and Year-End 2013 Financial Results and Host Conference Call on March 20, 2014
GlobeNewswire - Wed Mar 12, 6:00AM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, will announce its fourth quarter and year-end financial results for 2013 and give an operational update in a press release to be issued before the market opens on Thursday, March 20, 2014. The company will host a conference call that same day at 10:00 a.m. EDT to discuss its financial results.
Response Genetics, Inc. to Offer Expanded KRAS Mutation Test to Improve Treatment Decisions for Colorectal Cancer Patients
GlobeNewswire - Mon Mar 10, 6:13AM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer today announced the commercial availability of its expanded KRAS assay, a mutation detection test that provides broader coverage of KRAS mutations, including those in regions of the gene not previously examined.
2 Health Care Stocks Under $10 to Trade
at The Street - Thu Feb 20, 5:00AM CST
These health care stocks under $10 were trading higher on Wednesday. Here's how to trade them now.
4 Stocks Under $10 Making Big Moves
at The Street - Fri Feb 14, 5:30AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Response Genetics Receives Third GSK Milestone Payment
GlobeNewswire - Mon Jan 27, 6:00AM CST
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that it has achieved its third milestone payment from GlaxoSmithKline LLC ("GSK"
4 Under-$10 Health Care Stocks Moving Higher
at The Street - Fri Jan 17, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Response Genetics, Inc. Announces Contracts With Two Additional Blue Cross Blue Shield Plans
GlobeNewswire - Wed Dec 18, 6:00AM CST
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that it has signed agreements with two new Blue Cross Blue Shield health plans.
Response Genetics, Inc. Announces Pricing of Underwritten Public Offering
GlobeNewswire - Fri Dec 13, 8:00AM CST
Response Genetics, Inc. (Nasdaq:RGDX) (the "Company"
Response Genetics, Inc. Announces Proposed Underwritten Public Offering
GlobeNewswire - Thu Dec 12, 3:33PM CST
Response Genetics, Inc. (Nasdaq:RGDX) (the "Company"
Response Genetics, Inc. Announces Four New Contracts With National PPO Networks
GlobeNewswire - Wed Nov 13, 6:00AM CST
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that it has recently closed four new payor contracts with national Preferred Provider Organization ("PPO"
Response Genetics, Inc. Announces Third Quarter 2013 Financial Results
GlobeNewswire - Thu Nov 07, 6:00AM CST
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced its consolidated financial results and business progress for the third quarter ended September 30, 2013.
Response Genetics, Inc. to Release Third Quarter 2013 Financial Results and Host Conference Call on November 7, 2013
GlobeNewswire - Thu Oct 31, 6:00AM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, will announce its third quarter 2013 financial results and give an operational update in a press release to be issued before the market opens on Thursday, November 7, 2013. The company will host a conference call that same day at 10:00 a.m. EST to discuss its financial results.
Response Genetics, Inc. Announces $1.9 Million Registered Direct Offering
GlobeNewswire - Fri Sep 20, 7:45AM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, today announced that it has entered into definitive agreements with institutional investors for the sale of 932,805 shares of its common stock in a registered direct offering at $2.05 per share, the closing price on September 19, 2013. Gross proceeds of the offering, before deducting the placement agent fee and offering expenses, are expected to be approximately $1.9 million.